CXCR6-based immunotherapy in autoimmune, cancer and inflammatory infliction.
10.1016/j.apsb.2022.03.012
- Author:
Tingting LI
1
;
Jie PAN
2
;
Hongqi CHEN
3
;
Yongliang FANG
4
;
Yang SUN
2
Author Information
1. Department of Gastroenterology, the Second Medical Center, National Clinical Research Center for Geriatric Diseases, State Key Laboratory of Kidney Diseases, Chinese PLA General Hospital, Beijing 100853, China.
2. State Key Laboratory of Pharmaceutical Biotechnology, Department of Biotechnology and Pharmaceutical Sciences, School of Life Sciences, Nanjing University, Nanjing 210023, China.
3. Department of General Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai 200233, China.
4. Department of Urology, Boston Children's Hospital, Departments of Microbiology and Surgery, Harvard Medical School, Boston, MA 02115, USA.
- Publication Type:Journal Article
- Keywords:
Autoimmune diseases;
COVID-19;
CXCL16;
CXCR6;
Immunotherapy;
Inflammation;
Nonalcoholic steatohepatitis;
Tumor
- From:
Acta Pharmaceutica Sinica B
2022;12(8):3255-3262
- CountryChina
- Language:English
-
Abstract:
T cells, including both CD4+ and CD8+ T cells, play a pivotal role in mediating various inflammation and immune disorders. A long-standing challenge in T cell-based immunotherapy is to precisely inactivate or delete the pathogenic T cells in inflammation and autoimmune diseases, or to selectively expand the immunocompetent T cell in tumor or other immune compromised situations, without inducing global immunosuppression or zealous immune activation respectively. To achieve this, a specific marker is needed to differentiate the pathogenic or immunocompetent T cell among the rests. Indeed, recent progress of immunology strongly suggests that CXC chemokine receptor 6 (CXCR6, CD186) is such a kind of marker. Here, we review the emerging role of CXCR6 as a novel target for immunotherapy and discuss the underlying mechanism. We propose that CXCR6-based immunotherapy will play a significant role in autoimmune, nonalcoholic steatohepatitis (NASH), tumor, coronavirus disease 2019 (COVID-19) and even ageing-related inflammatory infliction.
